 |
|
Zidovudine Use to Reduce Perinatal HIV Type 1 Transmission in an Urban Medical Center
Andrew A. Wiznia, MD;
Marilyn Crane, CNM;
Genevieve Lambert, MD;
Jorge Sansary, MPH;
Adell Harris, MSW;
Laurie Solomon, MD
JAMA. 1996;275(19):1504-1506.
Abstract
| |
Objective.
—To evaluate whether zidovudine treatment was accepted and used by pregnant women subsequent to the release of the results of a multicenter, randomized, placebo-controlled trial (AIDS Clinical Trial Group [ACTG] Protocol 076) that showed that zidovudine significantly reduced maternal-infant human immunodeficiency virus (HIV) type 1 transmission.
Design.
—Prospective study.
Setting.
—A community hospital with an integrated, multidisciplinary HIV-dedicated program located in an impoverished, HIV-endemic urban setting.
Participants.
—All HIV-infected pregnant women identified after the release of the ACTG 076 results who were offered zidovudine therapy to reduce maternal-infant transmission.
Results.
—Only 49 of the 125 HIV-infected pregnant women delivering at our site during this study period were identified prenatally. Perinatal zidovudine therapy was chosen by 37 (75%) of 49 women. Women refusing zidovudine were more likely to report injection drug use as their HIV risk factor and to continue to use drugs during their pregnancy. Of women choosing zidovudine and delivering, 24 of 36 received all components of their elected therapy. The intrapartum dose was missed by 12 women, 4 of whom also missed their prescribed prenatal oral therapy. Lack of adherence to chosen therapy was associated with continued cocaine use during pregnancy.
Conclusions.
—Zidovudine therapy to interrupt vertical transmission of HIV was not widely used by these HIV-infected pregnant women. Further studies evaluating factors affecting the acceptance and use of recently published public health recommendations are needed.
(JAMA. 1996;275:1504-1506)
Author Affiliations
From the Division of Pediatric Infectious Disease (Drs Wiznia and Lambert, Mr Sansary, and Ms Harris), and the Department of Obstetrics/Gynecology (Ms Crane and Dr Solomon), Bronx (NY) Lebanon Hospital Center; and the Departments of Pediatrics (Drs Wiznia and Lambert) and Obstetrics/Gynecology (Ms Crane and Dr Solomon), Albert Einstein College of Medicine, Bronx, NY.
Footnotes
Reprints: Andrew Wiznia, MD, Bronx Lebanon Hospital Center, 1650 Selwyn Ave, Apt 2C, Bronx, NY 10457.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Outcomes After an Unstructured Treatment Interruption in Children and Adolescents With Perinatally Acquired HIV Infection
Saitoh et al.
Pediatrics 2008;121:e513-e521.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Universal Compared With Voluntary Screening for Human Immunodeficiency Virus Among Pregnant Women in Chicago
Immergluck et al.
Pediatrics 2000;105:54e-54.
ABSTRACT
| FULL TEXT
Translating Clinical Trial Results into Practice: The Effect of an AIDS Clinical Trial on Prescribed Antiretroviral Therapy for HIV-Infected Pregnant Women
Turner et al.
ANN INTERN MED 1999;130:979-986.
ABSTRACT
| FULL TEXT
Epidemiology and detection of HIV-1 among pregnant women in the United Kingdom: results from national surveillance 1988-96
Nicoll et al.
BMJ 1998;316:253-258.
ABSTRACT
| FULL TEXT
Perinatal HIV Infection: A Tale of Two States
JWatch Women's Health 1996;1996:17-17.
FULL TEXT
Reducing Mother-to-Infant Transmission of HIV -- The Door Remains Open
Landers and Sweet
NEJM 1996;334:1664-1665.
FULL TEXT
PROGRESS AND CHALLENGES IN PREVENTING PERINATAL HIV
JWatch General 1996;1996:2-2.
FULL TEXT
Preventing Perinatal HIV Infection: How Far Have We Come?
Simonds and Rogers
JAMA 1996;275:1514-1515.
ABSTRACT
|
